Molecular investigation of Blastocystis sp. and its subtypes in cancer patients under chemotherapy in Aegean region, Turkey

Simple item page
dc.contributor.authorÖncü Öner T.
dc.contributor.authorKarabey M.
dc.contributor.authorCan H.
dc.contributor.authorDeğirmenci Döşkaya A.
dc.contributor.authorKarakavuk M.
dc.contributor.authorGül A.
dc.contributor.authorKöseoğlu A.E.
dc.contributor.authorDöşkaya M.
dc.contributor.authorÜn C.
dc.contributor.authorGürüz A.Y.
dc.contributor.authorKaya S.
dc.contributor.authorPektaş B.
dc.contributor.authorAksoy Gökmen A.
dc.date.accessioned2024-07-22T08:04:06Z
dc.date.available2024-07-22T08:04:06Z
dc.date.issued2022
dc.description.abstractBlastocystis sp. is a common enteric protist found in humans and many other animals. Although the clinical relevance of Blastocystis sp. is currently fully unknown for humans, the prevalence of Blastocystis and subtypes are investigated in immunocompetent individuals presenting with symptoms like diarrhea or immunocompromised individuals including cancer patients. In this comprehensive study, the prevalence of Blastocystis sp. and subtypes were investigated in patients (n=94) with different types of malignant solid tumors using PCR targeting SSU rDNA gene and sequencing. All patients were undergoing chemotherapy and had diarrhea. According to obtained results, 46 patients were found to be Blastocystis positive and the molecular prevalence was detected as 48.9%. Among the positive specimens, 43 (43/46; 93.5%) of them were successfully subtyped. ST4 was the most predominant subtype and detected in 24 (55.8%) patients, followed by ST1 (11 patients, 25.6%) and ST3 (8 patients, 18.6%). In the colon cancer group, which had the highest number of patients, Blastocystis sp. was detected with a higher prevalence rate of 61.5% compared with the prevalence rate (48.9%) of all patients. Interestingly, ST3 was not detected in any of this patient group in contrast to ST4 and ST1. In conclusion, high prevalence of the Blastocystis in the immunocompromised patient groups shows the susceptibility of this patient group against any other infectious agents. © 2022
dc.identifier.DOI-ID10.1016/j.actatropica.2022.106577
dc.identifier.issn0001706X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12568
dc.language.isoEnglish
dc.publisherElsevier B.V.
dc.subjectAnimals
dc.subjectBlastocystis
dc.subjectBlastocystis Infections
dc.subjectDiarrhea
dc.subjectDNA, Protozoan
dc.subjectFeces
dc.subjectGenetic Variation
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPhylogeny
dc.subjectPrevalence
dc.subjectTurkey
dc.subjectTurkey
dc.subjectantineoplastic agent
dc.subjectribosome DNA
dc.subjectprotozoal DNA
dc.subjectcancer
dc.subjectchemotherapy
dc.subjectdiarrheal disease
dc.subjectdisease prevalence
dc.subjectmolecular analysis
dc.subjectpolymerase chain reaction
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectBlastocystis
dc.subjectblastocystosis
dc.subjectcancer chemotherapy
dc.subjectcancer patient
dc.subjectcolon cancer
dc.subjectcontrolled study
dc.subjectdiarrhea
dc.subjectfemale
dc.subjectgene sequence
dc.subjecthuman
dc.subjecthuman cell
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmolecular diagnosis
dc.subjectnonhuman
dc.subjectparasite identification
dc.subjectpolymerase chain reaction
dc.subjectprevalence
dc.subjectsolid malignant neoplasm
dc.subjectstrain identification
dc.subjectTurkey (republic)
dc.subjectanimal
dc.subjectblastocystosis
dc.subjectcomplication
dc.subjectdiarrhea
dc.subjectfeces
dc.subjectgenetic variation
dc.subjectgenetics
dc.subjectneoplasm
dc.subjectphylogeny
dc.subjectturkey (bird)
dc.titleMolecular investigation of Blastocystis sp. and its subtypes in cancer patients under chemotherapy in Aegean region, Turkey
dc.typeArticle

Files

Collections

Scopus Koleksiyonu